JP2011528896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528896A5 JP2011528896A5 JP2011519186A JP2011519186A JP2011528896A5 JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5 JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5
- Authority
- JP
- Japan
- Prior art keywords
- tuberculosis
- prevention
- protein sequence
- treatment
- rv2386c protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 claims 26
- 101700026505 mbtI Proteins 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 22
- 230000002265 prevention Effects 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 9
- 206010065048 Latent tuberculosis Diseases 0.000 claims 5
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 5
- 229920000023 polynucleotide Polymers 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 230000003111 delayed Effects 0.000 claims 2
- 102000037240 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (23)
- 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含む単離されたポリペプチドを含む、結核の治療または予防のための医薬。 - 結核の治療または予防が、潜伏結核の治療である、請求項1に記載の医薬。
- 結核の治療または予防が、潜伏結核の予防である、請求項1に記載の医薬。
- 結核の治療または予防が、結核の再活性化の予防である、請求項1に記載の医薬。
- 結核の治療または予防が、結核の再活性化の遅延である、請求項1に記載の医薬。
- 結核の治療または予防が、結核の治療である、請求項1に記載の医薬。
- 結核の治療または予防が、結核の予防である、請求項1に記載の医薬。
- 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチドをコードする核酸配列を含む単離されたポリヌクレオチドを含む、結核の治療または予防のための医薬。 - 結核の治療または予防が、潜伏結核の治療である、請求項8に記載の医薬。
- 結核の治療または予防が、潜伏結核の予防である、請求項8に記載の医薬。
- 結核の治療または予防が、結核の再活性化の予防である、請求項8に記載の医薬。
- 結核の治療または予防が、結核の再活性化の遅延である、請求項8に記載の医薬。
- 結核の治療または予防が、結核の治療である、請求項8に記載の医薬。
- 結核の治療または予防が、結核の予防である、請求項8に記載の医薬。
- 以下のもの:
(a) 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; もしくは
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチド、または
(b) (a)のポリペプチドをコードする核酸配列を含むポリヌクレオチド; および
(c) 製薬的に許容される担体または賦形剤
を含む医薬組成物。 - 以下のもの:
(a) 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; もしくは
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチド、または
(b) (a)のポリペプチドをコードする核酸配列を含むポリヌクレオチド; および
(c) 非特異的免疫応答エンハンサー
を含む免疫原性組成物。 - 医薬が、活動性結核を有する被験体用である、請求項1または8に記載の医薬。
- 医薬が、潜伏結核を有する被験体用である、請求項1または8に記載の医薬。
- 医薬が、結核を有さない被験体用である、請求項1または8に記載の医薬。
- 結核の治療または予防のための医薬の製造における、以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチドの、使用。 - 結核の治療または予防のための医薬の製造における、以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチドをコードする核酸配列を含むポリヌクレオチドの、使用。 - 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチドを含む融合タンパク質。 - 以下のもの:
(i) Rv2386cタンパク質配列;
(ii) Rv2386cタンパク質配列の変異体; または
(iii) Rv2386cタンパク質配列の免疫原性断片
を含むポリペプチドを含む融合タンパク質をコードするヌクレオチド配列を含むポリヌクレオチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8369908P | 2008-07-25 | 2008-07-25 | |
US61/083,699 | 2008-07-25 | ||
PCT/EP2009/059585 WO2010010179A1 (en) | 2008-07-25 | 2009-07-24 | The tuberculosis rv2386c protein, compositions and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015134587A Division JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Rv2386cタンパク質、組成物およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011528896A JP2011528896A (ja) | 2011-12-01 |
JP2011528896A5 true JP2011528896A5 (ja) | 2012-09-06 |
JP5981138B2 JP5981138B2 (ja) | 2016-08-31 |
Family
ID=41227131
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011519186A Active JP5981138B2 (ja) | 2008-07-25 | 2009-07-24 | 結核Rv2386cタンパク質、組成物およびその使用 |
JP2015134587A Active JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Rv2386cタンパク質、組成物およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015134587A Active JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Rv2386cタンパク質、組成物およびその使用 |
Country Status (23)
Country | Link |
---|---|
US (4) | US20110206712A1 (ja) |
EP (1) | EP2315834B1 (ja) |
JP (2) | JP5981138B2 (ja) |
KR (1) | KR20110049834A (ja) |
CN (2) | CN106866801A (ja) |
AU (1) | AU2009273132B2 (ja) |
BR (1) | BRPI0916704A2 (ja) |
CA (1) | CA2731547C (ja) |
CO (1) | CO6351811A2 (ja) |
CY (1) | CY1121632T1 (ja) |
DK (1) | DK2315834T3 (ja) |
EA (1) | EA201100070A1 (ja) |
ES (1) | ES2685498T3 (ja) |
HR (1) | HRP20181353T1 (ja) |
HU (1) | HUE039159T2 (ja) |
IL (1) | IL210589A (ja) |
LT (1) | LT2315834T (ja) |
MX (1) | MX2011000982A (ja) |
PL (1) | PL2315834T3 (ja) |
PT (1) | PT2315834T (ja) |
SI (1) | SI2315834T1 (ja) |
UA (1) | UA107329C2 (ja) |
WO (1) | WO2010010179A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2441469A1 (en) * | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
US20110189217A1 (en) | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
EP2315834B1 (en) * | 2008-07-25 | 2018-06-13 | GlaxoSmithKline Biologicals S.A. | The tuberculosis rv2386c protein, compositions and uses thereof |
SG10201505149WA (en) * | 2008-07-25 | 2015-07-30 | Glaxosmithkline Biolog Sa | Novel compositions and methods |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
CN107478849B (zh) * | 2013-05-31 | 2019-08-20 | 中国医学科学院病原生物学研究所 | 用于结核病诊断和预防的蛋白 |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
JP6781698B2 (ja) * | 2014-08-15 | 2020-11-04 | オックスフォード イミュノテック リミテッド | 結核菌(Mycobacterium tuberculosis)タンパク質 |
CN105572352B (zh) * | 2016-02-17 | 2017-07-28 | 遵义医学院附属医院 | 一组结核潜伏感染诊断标志物及其用途 |
US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
BR112019025193A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução |
JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
CN109234414B (zh) * | 2018-06-29 | 2022-05-17 | 周琳 | 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用 |
CN108866213A (zh) * | 2018-06-29 | 2018-11-23 | 周琳 | 结核分枝杆菌利福平耐药性诊断标志物及其应用 |
CN108950031A (zh) * | 2018-06-29 | 2018-12-07 | 周琳 | 结核分枝杆菌的利福平耐药性诊断标志物及其应用 |
US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
CN114222762A (zh) * | 2019-06-14 | 2022-03-22 | 史坦恩斯血清研究所 | 用于结核疫苗的融合蛋白 |
CN112457410B (zh) * | 2020-11-05 | 2023-04-07 | 迈克生物股份有限公司 | 用于结核分枝杆菌感染检测的抗原组合物 |
DE202022102137U1 (de) | 2022-04-21 | 2022-04-28 | Damayanthi Dalu | Eine neue Zusammensetzung zur Behandlung von Tuberkulose |
CN115725607B (zh) * | 2022-07-14 | 2023-11-28 | 山东第一医科大学附属省立医院(山东省立医院) | 一种鼻疽诺卡菌的致病靶基因及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
US7087713B2 (en) | 2000-02-25 | 2006-08-08 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
NZ507378A (en) | 1998-04-07 | 2002-12-20 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
ES2333579T3 (es) | 2000-06-20 | 2010-02-24 | Corixa Corporation | Proteinas de fusion de mycobacterium tuberculosis. |
AU2002302919A1 (en) | 2001-02-22 | 2002-10-03 | Institut Pasteur | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
AU2003213118A1 (en) | 2002-02-15 | 2003-09-09 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
US20030236393A1 (en) | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
US7424370B2 (en) | 2004-02-06 | 2008-09-09 | Council Of Scientific And Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
PT2426141E (pt) * | 2005-04-29 | 2014-11-25 | Glaxosmithkline Biolog Sa | Método para prevenção ou tratamento de uma infecção por m. tuberculosis |
WO2008007942A1 (en) | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
MX362698B (es) | 2007-03-02 | 2019-02-01 | Glaxosmithkline Biologicals Sa | Metodo novedoso y composiciones. |
SI2315773T1 (sl) | 2008-07-25 | 2016-12-30 | Glaxosmithkline Biologicals S.A. | Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze |
EP2315834B1 (en) * | 2008-07-25 | 2018-06-13 | GlaxoSmithKline Biologicals S.A. | The tuberculosis rv2386c protein, compositions and uses thereof |
WO2010010178A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
SG10201505149WA (en) | 2008-07-25 | 2015-07-30 | Glaxosmithkline Biolog Sa | Novel compositions and methods |
PL2421557T3 (pl) | 2009-04-24 | 2019-07-31 | Statens Serum Institut | Szczepionka przeciwko gruźlicy do zapobiegania reaktywacji |
US8367055B2 (en) | 2009-05-14 | 2013-02-05 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
PL2528621T3 (pl) | 2010-01-27 | 2017-07-31 | Glaxosmithkline Biologicals S.A. | Zmodyfikowane antygeny gruźlicy |
-
2009
- 2009-07-24 EP EP09781057.6A patent/EP2315834B1/en active Active
- 2009-07-24 MX MX2011000982A patent/MX2011000982A/es active IP Right Grant
- 2009-07-24 CN CN201710068231.XA patent/CN106866801A/zh active Pending
- 2009-07-24 ES ES09781057.6T patent/ES2685498T3/es active Active
- 2009-07-24 SI SI200931869T patent/SI2315834T1/sl unknown
- 2009-07-24 UA UAA201100300A patent/UA107329C2/uk unknown
- 2009-07-24 CA CA2731547A patent/CA2731547C/en active Active
- 2009-07-24 LT LTEP09781057.6T patent/LT2315834T/lt unknown
- 2009-07-24 DK DK09781057.6T patent/DK2315834T3/en active
- 2009-07-24 JP JP2011519186A patent/JP5981138B2/ja active Active
- 2009-07-24 PT PT97810576T patent/PT2315834T/pt unknown
- 2009-07-24 KR KR1020117004639A patent/KR20110049834A/ko not_active Application Discontinuation
- 2009-07-24 EA EA201100070A patent/EA201100070A1/ru unknown
- 2009-07-24 BR BRPI0916704-8A patent/BRPI0916704A2/pt not_active IP Right Cessation
- 2009-07-24 US US13/055,787 patent/US20110206712A1/en not_active Abandoned
- 2009-07-24 WO PCT/EP2009/059585 patent/WO2010010179A1/en active Application Filing
- 2009-07-24 AU AU2009273132A patent/AU2009273132B2/en not_active Ceased
- 2009-07-24 HU HUE09781057A patent/HUE039159T2/hu unknown
- 2009-07-24 PL PL09781057T patent/PL2315834T3/pl unknown
- 2009-07-24 CN CN200980138405.9A patent/CN102165064B/zh active Active
-
2011
- 2011-01-12 IL IL210589A patent/IL210589A/en not_active IP Right Cessation
- 2011-01-27 CO CO11009237A patent/CO6351811A2/es not_active Application Discontinuation
-
2013
- 2013-06-27 US US13/929,232 patent/US20140086948A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/283,727 patent/US9480735B2/en active Active
-
2015
- 2015-07-03 JP JP2015134587A patent/JP6104326B2/ja active Active
-
2016
- 2016-09-15 US US15/266,220 patent/US10286053B2/en active Active
-
2018
- 2018-08-23 HR HRP20181353TT patent/HRP20181353T1/hr unknown
- 2018-08-24 CY CY20181100883T patent/CY1121632T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011528896A5 (ja) | ||
JP2011528895A5 (ja) | ||
JP2011528897A5 (ja) | ||
JP2012126742A5 (ja) | ||
JP2012136541A5 (ja) | ||
HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
JP2013231081A5 (ja) | ||
CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
JP2016128513A5 (ja) | ||
JP2011136997A5 (ja) | ||
JP2014051497A5 (ja) | ||
JP2012115277A5 (ja) | ||
JP2011500073A5 (ja) | ||
JP2014507144A5 (ja) | 慢性b型肝炎感染症のための酵母系免疫療法組成物 | |
JP2014530220A5 (ja) | ||
JP2008529558A5 (ja) | ||
JP2010512795A5 (ja) | ||
JP2008508859A5 (ja) | ||
JP2015096557A5 (ja) | ||
JP2008530245A5 (ja) | ||
JP2015518818A5 (ja) | ||
JP2015510393A5 (ja) | ||
JP2010534684A5 (ja) | ||
JP2009213477A5 (ja) | ||
JP2010503396A5 (ja) |